Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

2 Mar 2007

Abstract excerpt

Bcl family members Bcl-2, Bcl-x(L), and Mcl-1, are frequently expressed and implicated in the survival of myeloma cells. Obatoclax (GX015-070) is a novel, small-molecule antagonist of the BH3-binding groove of the Bcl family of proteins. We show that GX015-070 inhibits the binding of Bak to Mcl-1, up-regulates Bim, induces cytochrome c release, and activates capase-3 in human myeloma cell lines (HMCLs),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17332241
DOI: 10.1182/blood-2006-10-047951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaPMID 17332241Read ↗

Targeting Bcl-2 for the treatment of multiple myeloma.Semantic proximity Read ↗

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisSemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature reviewSemantic proximity Read ↗

ABT-737 is highly effective against molecular subgroups of multiple myelomaSemantic proximity Read ↗

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Semantic proximity Read ↗

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.Semantic proximity Read ↗

Anti-cancer drug discovery and developmentSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.Semantic proximity Read ↗

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.